SynthesisJournal of the Chinese Medical Association : JCMA2026
A global perspective on prognosis in acral and nonacral cutaneous melanoma: A systematic review and meta-analysis.
Synthesis in Journal of the Chinese Medical Association : JCMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcral melanoma (AM) is a rare cutaneous malignancy associated with poor survival. However, prognostic differences between AM and nonacral cutaneous melanoma (NAM) remain unclear. Therefore, we conducted a systematic review and meta-analysis to compare survival outcomes between patients with AM and those with NAM.
methodsPubMed, EMBASE, and the Cochrane Library were comprehensively searched for studies published between January 2000 and December 2025. Studies comparing the 5-year overall survival (OS) and 5-year relapse-free survival (RFS) between AM and NAM were included. Subgroup analyses were performed by disease stage and ethnicity to assess their impact on melanoma prognosis.
resultsTwenty studies (18 retrospective and two prospective cohort studies) involving 568 346 patients were included. The meta-analysis demonstrated that AM was associated with significantly lower 5-year OS than NAM (risk ratio [RR]: 0.89; 95% CI: 0.86-0.92; p < 0.00001). In subgroup analyses, compared with NAM, AM was associated with poorer 5-year OS in both stage II (RR: 0.92; 95% CI: 0.88-0.96; p = 0.0003) and stage III disease (RR: 0.85; 95% CI: 0.75-0.96; p = 0.01). Additionally, patients from darker-skinned populations with AM had poorer 5-year OS than those from White populations (RR: 0.89; 95% CI: 0.83-0.95; p = 0.0006).
conclusionPatients with AM exhibited markedly lower 5-year OS than those with NAM, particularly among patients with stage II and III. Moreover, individuals from darker-skinned populations with AM had poorer survival outcomes than those from White populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.